Johnson & Johnson Announces New Two-year Results From Its Phase 3 ICONIC-LEAD Study Evaluating ICOTYDE In Adults With Moderate-To-Severe Plaque Psoriasis; Data Demonstrated Consistently High Levels Of Skin Clearance And Patient-Reported Symptom Improvement At Week 112, With No New Safety Signals

Johnson & Johnson announced results from its Phase 3 ICONIC-LEAD study for ICOTYDE, a treatment for moderate-to-severe plaque psoriasis. At Week 112, over 72% of patients achieved a PASI score of 90, with 44% achieving complete skin clearance (PASI 100). The study also reported sustained improvement in itch for 78% of patients, and no new safety signals were identified, maintaining the established safety profile of ICOTYDE.